Orthopaedic Hospital v. DJO Global, Inc.

District Court, S.D. California·Decided August 23, 2021·No. 3:19-cv-00970·Unknown

Opinion

1 2 3 4 5 6 7 10 11 ORTHOPAEDIC HOSPITAL, Case No.: 3:19-cv-00970-JLS-AHG

12 Plaintiff, ORDER REGARDING 13 v. DEFENDANT’S MOTION TO COMPEL AND FOR SANCTIONS 14 DJO GLOBAL, INC. and DJO FOLLOWING IN CAMERA FINANCE, LLC, Defendants. 16

17 [ECF No. 173] 18

28 2 On July 1, 2021, the Court issued an Order Granting in Part and Deferring in Part 3 Defendant’s Motion to Compel and for Sanctions (ECF No. 173) (“Motion to Compel”). 4 ECF No. 238 (the “July 1 Order”). The July 1 Order concerned a discovery dispute 5 regarding Defendant’s pursuit of materials from a prior litigation involving Plaintiff and 6 the patents-in-suit (the “DePuy litigation”). 7 As discussed in the July 1 Order, the parties’ dispute regarding DePuy litigation 8 materials was first addressed in part by the Court in its December 22, 2020 Order (ECF 9 No. 144) granting in part and denying in part the relief sought by Defendant in the parties’ 10 Joint Motion for Resolution of Discovery Dispute (ECF No. 106). In compliance with that 11 Order, Plaintiff provided a supplemental privilege log (“First Supplemental Privilege 12 Log”) to Defendant by the Court-imposed deadline of January 11, 2021. See ECF No. 173- 13 7. In the Motion to Compel, Defendant argued that the First Supplemental Privilege Log 14 did not comply with the December 22 Order, because the descriptions were insufficient to 15 allow Defendant to verify the claims of privilege, and, more significantly, Defendant 16 contended the log still failed to account for numerous withheld and redacted documents. 17 ECF No. 173 at 8. After meeting and conferring, Plaintiff produced a Second Supplemental 18 Privilege Log and additional documents on February 12, 2021. See ECF No. 173-11. After 19 further meet-and-confer attempts and a discovery conference with the Court, Defendant 20 brought the Motion to Compel. ECF No. 173. 21 In its motion, Defendant contended that Plaintiff had improperly refused to produce 22 all documents responsive to Defendant’s Request No. 36 in its First Set of Requests for 23 Production of Documents (“RFP No. 36”), which sought “[a]ll pleadings discovery, expert 24 reports and disclosures, and correspondence from [the DePuy litigation].” ECF No. 173-2 25 at 48. Defendant further asserted that the new materials Plaintiff produced on 26 February 12, 2021—including 13 new documents, 9 unredacted copies of previously 27 redacted documents, 25 new privilege log entries, and 14 revisions of existing log entries— 28 “strongly suggest[] that [Plaintiff’s] withholding of the information is less than innocent.” 1 ECF No. 173 at 9. To remedy Plaintiff’s purported misconduct, Defendant asked the Court 2 to (1) conduct in camera review of the DePuy litigation documents that Plaintiff continued 3 to withhold and redact, (2) compel Plaintiff to produce all non-privileged documents 4 responsive to RFP No. 36 “related to patent infringement, damages, or validity,”1 and (3) 5 impose fee-shifting sanctions on Plaintiff. 6 In the July 1 Order, the Court granted Defendant’s motion to compel the depositions 7 of Richard Tarr and Brian Tomko from the DePuy litigation, which Plaintiff had withheld 8 as non-responsive but not privileged, and granted Defendant’s request for in camera review 9 of certain other materials from the DePuy litigation that Plaintiff had redacted on the basis 10 of privilege. See ECF No. 238. The Court deferred ruling on Defendant’s request for 11 sanctions pending the completion of its in camera review. 13 The documents subject to in camera review included the unredacted versions of: (1) 14 the deposition transcript of Dr. Mark Hanes; (2) the deposition transcript of Venkat 15 Narayan; (3) the deposition transcript of Dr. Fu-Wen Shen; and (4) certain of Plaintiff’s 16 discovery responses from the DePuy litigation (ECF Nos. 172-10, 172-11, 172-12), with 17 certain exceptions.2 Having conducted the in camera review of these materials, the Court 18 finds as follows: 19 \\ 20 21 1 During the meet-and-confer process, the parties had agreed to narrow the scope of RFP 22 No. 36 to documents within these parameters. ECF No. 173-3 at 3. 23 2 Plaintiff was not required to produce its responses to DePuy’s Interrogatories Nos. 8 or 24 10 to the Court for in camera review, because the Court found Defendant failed to meet its 25 burden under the test set forth in United States v. Zolin, 491 U.S. 554, 572 (1989) to “show a factual basis sufficient to support a reasonable, good faith belief that in camera inspection 26 may reveal evidence that information in the materials is not privileged.” See In re Grand 27 Jury Investigation, 974 F.2d 1068, 1075 (9th Cir. 1992) (applying the Zolin test to determine the propriety of in camera review of materials subject to a claimed attorney- 28 1 A. Deposition of Dr. Mark Hanes (ECF No. 172-7) 2 As discussed in the Court’s July 1 Order, the Hanes Deposition description in 3 Plaintiff’s First Supplemental Privilege Log reads: “Litigation document reflecting 4 communications between M. Hanes and patent prosecution counsel acting on behalf of 5 DePuy and [Plaintiff] regarding prosecution strategy.” ECF No. 173-7 at 53. In contrast, 6 the Hanes deposition description in the Second Supplemental Privilege Log (current) reads: 7 “Redacted deposition testimony discussing communication between M. Hanes, H. 8 McKellop, and ‘prosecution counsel’ regarding 110 Patent Family patent applications.” 9 ECF No. 173-11 at 2. 10 The Court has reviewed the redacted portions of the Hanes Deposition at 23:14- 11 27:17, 43:10-19, 44:17-45:7, 45:19-46:24, 47:16-48:9, 50:16-63:7, 181:18-198:5, 203:13- 12 208:9, 211:10-218:4, 237:11-251:3, and 252:23-253:18. See ECF No. 172-7. For 13 simplicity, the Court treats these as five portions of deposition testimony (pages 23-27, 43- 14 63, 181-198, 203-218, and 237-253) and will address each portion in turn to evaluate 15 whether Plaintiff’s privilege log entry is adequate. 16 i. Pages 23-27 17 The Court finds the portion of the Hanes Deposition at 23:14-27:17 is not privileged. 18 Dr. Hanes’s deposition testimony in this section concerns whether he believed 19 Orthopaedic Hospital would be entitled to royalties for any products that DePuy sold 20 containing AOX, based on his opinion about whether the Hospital’s pending patent 21 application claims covered AOX. Dr. Hanes is an engineer, not an attorney, and gives no 22 indication in his testimony that his opinion is based on communications with “prosecution 23 counsel.” During the Court’s hearing on Defendant’s motion, Plaintiff explained that the 24 reason it did not identify “prosecution counsel” in its privilege log entries is because 25 “prosecution counsel” was not identified in the corresponding materials. Dr. Hanes makes 26 no reference to “prosecution counsel” in this portion of his testimony. The only 27 communication discussed is an email between Dr. Hanes and Matt Reimink, who is not 28 identified as an attorney and, when Dr. Hanes was asked his title, he stated that Mr. 1 Reimink “was in hip development. I don’t recall his title at that time.” Hanes Dep. 27:9- 2 11. Therefore, if anything, Dr. Hanes’s testimony suggests Mr. Reimink is not “prosecution 3 counsel.” 4 Plaintiff is ORDERED to produce 23:14-27:17 of the Hanes Deposition to 5 Defendant. 6 ii. Pages 43-63 7 The Court finds that the deposition testimony at 44:17-45:7, 46:15-24, and 47:16- 8 48:9 of the Hanes Deposition is privileged and was properly logged. 9 The testimony at lines 43:10-19 and 45:19-46:14 is not privileged. This portion of 10 testimony reveals the fact that Dr.

Free access — add to your briefcase to read the full text and ask questions with AI

Orthopaedic Hospital v. DJO Global, Inc., (S.D. Cal. 2021).

Orthopaedic Hospital v. DJO Global, Inc. (Orthopaedic Hospital v. DJO Global, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

United States v. Zolin
491 U.S. 554 (Supreme Court, 1989)
Doe v. City of Chula Vista
196 F.R.D. 562 (S.D. California, 1999)